Utah Doc Banned from Prescribing Pills After License Surrender
Published Date: 7/22/2025
Notice
Summary
Dr. Thomas Draschil from Utah lost his DEA registration because he gave up his state medical and controlled substance licenses last year. Since he didn’t ask for a hearing, the DEA officially canceled his right to handle controlled substances starting July 22, 2025. This means he can no longer legally prescribe or manage controlled drugs, affecting his medical practice and any related income.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Draschil
Dr. Thomas Draschil's DEA Certificate of Registration No. FD9980118 is revoked and the Order is effective August 21, 2025. Because his Utah physician license and Utah controlled-substance license were voluntarily surrendered on July 29, 2024, he is not authorized to handle, prescribe, dispense, or administer controlled substances in Utah.
Pending Renewal and New Registrations Denied
The DEA denied any pending applications by Thomas Draschil to renew or modify his registration and denied any pending application for additional registration in Utah, with that denial effective August 21, 2025. The Order follows findings that he is not licensed as a practitioner in Utah.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17531, Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
The Drug Enforcement Administration (DEA) issues this temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4- yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4- chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3- (1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, to schedule I under the Controlled Substances Act. DEA bases this action on a finding that placing 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N- propionitrile chlorphine, and spirochlorphine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.
2026-17429, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.
2026-17385, Importer of Controlled Substances Application: Experic LLC
Experic LLC wants to become an official importer of some controlled substances, including certain drugs like tetrahydrocannabinols and nabilone. People and companies already registered can share their thoughts or ask for a hearing by September 25, 2026. This move could impact businesses dealing with these substances, so keep an eye on the deadline to have your say!
2026-17276, Importer of Controlled Substances Application: Biopharmaceutical Research Company
Biopharmaceutical Research Company has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Previous / Next Documents
Previous: 2025-13712, Notice of Request for Revision to and Extension of Approval of an Information Collection; Federal Plant Pest and Noxious Weed Regulations
The Animal and Plant Health Inspection Service wants to update and keep approval for a form that helps control harmful plant pests and noxious weeds. This affects farmers, gardeners, and businesses dealing with plants, making sure they follow the rules to keep plants safe. They’re asking for more time to collect this info, with no new costs expected, so everyone can keep protecting our green spaces.
Next: 2025-13716, Proposed Collection; Comment Request; Extension: Form 18-K-Annual Report
The SEC wants to keep using Form 18-K, an annual report that foreign governments with U.S. securities must file. About 37 groups spend around 8 hours each year filling it out, with no extra costs involved. The SEC is asking for public comments by September 22, 2025, to make sure this form stays useful and easy to handle.